NT PHARMA (01011) has significant objections to the ruling and has engaged a compliance legal service team to initiate statutory procedures for the application to revoke the ruling.

NT PHARMA (01011) announced that on July 20, 2026, it received the arbitration award No. 1519 (2026) from the China International Economic and Trade Arbitration Commission. This arbitration matter stems from the guarantee arrangement related to the asset transaction project signed by the company with the relevant entities of Beijing Konruns Pharmaceutical Co., Ltd. in 2020, with the corresponding equity transfer having been completed in 2020. The award stipulates that the company and the relevant joint and several liability parties are to pay a penalty, related fees, and arbitration sharing amounts totaling approximately RMB 92 million. The company holds significant objections to this award and has engaged a compliance legal service team to initiate the statutory procedures to apply for the annulment of the award. Currently, the award is still within the statutory period during which it can be legally annulled, and the related payment obligation has not yet entered the enforcement stage. The Group is carefully assessing the potential financial impact in line with the liability-sharing arrangement of the joint and several parties and the liability boundaries of the subjects that have completed bankruptcy reorganization. The Group's daily operations and cash flow are currently maintaining a normal state.